Company: AIBT
Filing Date: 2025-07-03
Form Type: 253G2
Source: 0001096906-25-001087
Chunk: 64

Company: AIBOTICS, INC.
Filing Date: 2025-07-03
Form: 253G2
Chunk 64
---
31, |
| 2025      |     |         2024 |

| Intellectual property          | $ | 2,000,000 |     | $ | 2,000,000 |
| Less: accumulated amortization |   |  -892,336 |     |   |  -728,102 |
| Intangible assets, net         | $ | 1,107,664 |     | $ | 1,271,898 |

Amortization expense from intangible assets was $164,234 and $166,058 for the three months ended March 31, 2025, and 2024. Future amortization expense from intangible assets as of March 31, 2025, were as follows:

|                                      |     | For the Year Ended, |           |
|:-------------------------------------|:----|:--------------------|----------:|
|                                      |     | December 31,        |           |
| Remainder of 2025                    |     | $                   |   501,825 |
| 2026                                 |     |                     |   605,839 |
| Thereafter                           |     |                     |         - |
| Total remaining amortization expense |     | $                   | 1,107,664 |

NOTE 5 – RELATED PARTY TRANSACTIONS Notes Payable – Related Parties On January 30 th, 2024, the Company signed an agreement with a major shareholder for a $165,000 note payable. The note accrues interest at a rate of 1.75% compounded annually and has a maturity date of January 30, 2025 (Note 6 – Promissory and Convertible Notes). The note had interest expense of $3,370 for the three months ended as of March 31, 2025, respectively. As of March 31, 2025, the Company had recorded accrued interest of $3,370 related to the note within accrued interest on the Condensed Consolidated Balance Sheet. AIBiotics Consulting Agreement with the CEO On November 17, 2021, AIBiotics entered into an Executive Consulting Agreement (the “AIBiotics Consulting Agreement”), with Benjamin Kaplan (“BK”) to serve as the Company’s CEO for an initial term of 36 months. As of March 31, 2025 and December 31, 2024, the Company had cash compensation outstanding as accrued expense - related party due to the AIBiotics Consulting Agreement of $936,000 and $864,